Health

By the Retiree Report Editorial Team · Updated 2026-05-16 · 7 min read

This article is general information, not medical advice. Talk with a licensed clinician before making any decision about your care.

Does Medicare cover Ozempic and Wegovy in 2026? The fine print

Medicare still won’t pay for a GLP-1 drug used purely to lose weight — that prohibition has been on the books since 2003. But the answer is no longer a flat no. Ozempic is covered for type 2 diabetes, Wegovy is covered when it’s prescribed to lower the risk of heart attack or stroke, and a new $50-a-month federal demonstration called the Medicare GLP-1 Bridge opens July 1, 2026, for people who meet specific BMI and health criteria.

Why Medicare has refused to cover weight-loss drugs for two decades

The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 — the same law that created Part D — explicitly excluded “agents when used for anorexia, weight loss, or weight gain” from the program’s covered drugs. That exclusion was a political compromise rooted in memories of fen-phen, an obesity drug combination pulled from the market in 1997 after being linked to heart-valve damage. For 20 years, that single sentence in the statute meant a Part D plan could not pay for a drug whose only FDA-approved use was weight loss, no matter how effective the drug was.

That hasn’t changed in 2026. According to a KFF analysis, the underlying statutory exclusion is still in force. What’s shifted is the way the FDA has expanded the labels on these drugs — and how the Centers for Medicare & Medicaid Services has interpreted those new labels. Once a GLP-1 picks up an approved indication other than weight loss, Part D plans can cover it for that indication.

When Medicare actually pays for Ozempic, Wegovy, and Zepbound today

Ozempic, Wegovy, Mounjaro, and Zepbound all belong to a family called GLP-1 receptor agonists, but they’re labeled for different things. Ozempic (semaglutide) is approved for type 2 diabetes and to lower cardiovascular risk in diabetic adults with heart disease, so it sits on most Part D formularies as a diabetes drug. Mounjaro (tirzepatide) is also a diabetes drug. Wegovy and Zepbound are the same two molecules, just labeled and dosed for chronic weight management — and that’s the labeling Medicare can’t pay for on its own.

The hinge moment came in March 2024. The FDA approved a new use for Wegovy — reducing the risk of cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease who are also overweight or obese. The clinical trial behind it followed more than 17,000 patients and showed major cardiovascular events in 6.5% of Wegovy users versus 8% on placebo. Within weeks, CMS told Part D plans they could put Wegovy on their formularies for the new heart-disease use, even though the same drug remained off-limits when prescribed only for weight loss. KFF estimates roughly 3.6 million Medicare beneficiaries — about 7% of the program — fit that cardiovascular profile.

AARP reports that Medicare also covers Wegovy when prescribed for MASH, a serious liver condition, and that Ozempic is covered when used for chronic kidney disease in people with diabetes. None of those count as a weight-loss prescription, even when the patient also loses weight on the drug. The label and the diagnosis on the prescription are what determine whether your plan pays.

The new Medicare GLP-1 Bridge: $50 a month starting July 1, 2026

This is the big change for older Americans this year. CMS is launching a temporary demonstration program that, for the first time, will let Medicare beneficiaries fill GLP-1 prescriptions for weight loss at a flat copay of $50 a month. According to CMS’s Medicare GLP-1 Bridge page, the program runs from July 1, 2026, through December 31, 2027, and covers all formulations of Wegovy and Foundayo plus the KwikPen formulation of Zepbound.

You have to be enrolled in a Medicare Part D plan, and you have to meet one of two clinical pathways at the time you start the drug. The first pathway is straightforward: you’re 18 or older with a body mass index of 35 or higher, and the prescription is paired with a structured diet and exercise plan. The second pathway opens the door at a lower BMI of 27 if you also have prediabetes (defined by American Diabetes Association guidelines), a prior heart attack, a prior stroke, or symptomatic peripheral artery disease. A prescriber has to attest you meet the criteria.

Read the fine print carefully. According to KFF’s analysis of the program, the $50 copay does not count toward your Part D deductible, and it does not count toward your annual out-of-pocket maximum — which for 2026 is $2,100, per the CMS Final CY 2026 Part D Redesign Program Instructions. For someone with high-cost drugs in addition to a GLP-1, that’s a real disadvantage: the $50 sits outside the new spending cap that protects you from runaway pharmacy bills. We explain how that ceiling works in our guide to the 2026 Part D out-of-pocket cap.

What this changes — and what it doesn’t

The Bridge is significant because the cash list price for these drugs is brutal. KFF puts Wegovy’s list price at roughly $1,300 a month. Even on Part D plans where Wegovy is covered for cardiovascular use, beneficiaries on a specialty tier can owe 25% to 33% coinsurance until they hit the $2,100 cap, which works out to several hundred dollars a month. A flat $50 copay, by contrast, is predictable and doesn’t change with the dose.

The Bridge is also notable for what it isn’t. It is not a permanent benefit. It expires at the end of 2027 unless Congress or a future administration extends it. Plans don’t have to participate in the operations side, and the $50 doesn’t flow through your Part D deductible or cap. CMS had originally intended to fold these drugs into a broader, longer-term program called the BALANCE Model — short for Better Approaches to Lifestyle and Nutrition for Comprehensive Health — that would have negotiated a price of about $245 per month for GLP-1s in both Medicare and Medicaid. KFF reports that BALANCE has been indefinitely delayed in Medicare after fewer than the required 80% of Part D plan sponsors agreed to participate, though the Medicaid version is moving ahead in May 2026.

There are also drugs the Bridge does not cover. Ozempic and Mounjaro are not on the Bridge list, because they’re already covered under Part D for diabetes. Compounded semaglutide and tirzepatide — the cheaper, custom-mixed versions some patients have been buying from telehealth services — are not in the Bridge either, and FDA has tightened enforcement against most of those compounded products as the original drugs have come off the official shortage list.

What to do if you think you might qualify

Start with your prescriber, not your plan. The Bridge requires a clinical attestation that you meet the BMI and comorbidity criteria, so the conversation belongs in your doctor’s office. If you’ve never had your BMI calculated as part of a recent visit, ask. If you have a history of a heart attack, stroke, or peripheral artery disease, make sure those diagnoses are documented in your chart. None of this is a guarantee the drug is right for you — GLP-1s have real side effects, including nausea, gallbladder problems, and pancreatitis, and they’re not appropriate for everyone — so the risk-benefit conversation matters more than the paperwork.

If you’re already on Medicare and shopping for next year’s plan, run your prescriptions through the official Medicare Plan Finder before signing anything. Plans handle GLP-1s very differently: some put them on a high specialty tier with prior authorization, some leave them off the formulary entirely. We walk through the tool step by step in our Plan Finder walkthrough. And if cost is the real barrier, both Novo Nordisk (Wegovy, Ozempic) and Eli Lilly (Zepbound, Mounjaro) run patient assistance programs for people who don’t qualify for Medicare coverage; ask your prescriber’s office to help you apply.

What to remember

Medicare’s blanket ban on paying for weight-loss drugs is still on the books, but the wall has cracks. If you have type 2 diabetes, Ozempic is likely covered. If you have heart disease and a high BMI, Wegovy is likely covered. And starting July 1, 2026, a temporary federal program will let qualifying Part D members fill Wegovy, Zepbound KwikPen, or Foundayo for a flat $50 a month — a meaningful break, even though it doesn’t count toward your annual drug cap. None of this is medical advice; talk to your doctor about whether a GLP-1 belongs in your treatment plan, and read your plan’s formulary before you assume anything is covered.